Frontiers in Oncology (Dec 2021)
Patient-Derived Explants as a Precision Medicine Patient-Proximal Testing Platform Informing Cancer Management
- Abby R. Templeton,
- Abby R. Templeton,
- Abby R. Templeton,
- Abby R. Templeton,
- Penny L. Jeffery,
- Penny L. Jeffery,
- Penny L. Jeffery,
- Penny L. Jeffery,
- Patrick B. Thomas,
- Patrick B. Thomas,
- Patrick B. Thomas,
- Patrick B. Thomas,
- Mahasha P. J. Perera,
- Mahasha P. J. Perera,
- Mahasha P. J. Perera,
- Mahasha P. J. Perera,
- Mahasha P. J. Perera,
- Gary Ng,
- Gary Ng,
- Alivia R. Calabrese,
- Alivia R. Calabrese,
- Alivia R. Calabrese,
- Alivia R. Calabrese,
- Clarissa Nicholls,
- Clarissa Nicholls,
- Clarissa Nicholls,
- Nathan J. Mackenzie,
- Nathan J. Mackenzie,
- Nathan J. Mackenzie,
- Nathan J. Mackenzie,
- Jack Wood,
- Jack Wood,
- Jack Wood,
- Laura J. Bray,
- Laura J. Bray,
- Laura J. Bray,
- Ian Vela,
- Ian Vela,
- Ian Vela,
- Ian Vela,
- Ian Vela,
- Erik W. Thompson,
- Erik W. Thompson,
- Elizabeth D. Williams,
- Elizabeth D. Williams,
- Elizabeth D. Williams,
- Elizabeth D. Williams
Affiliations
- Abby R. Templeton
- School of Biomedical Sciences at the Translational Research Institute (TRI), Queensland University of Technology (QUT), Brisbane, QLD, Australia
- Abby R. Templeton
- Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD, Australia
- Abby R. Templeton
- Queensland Bladder Cancer Initiative (QBCI), Brisbane, QLD, Australia
- Abby R. Templeton
- Australian Prostate Cancer Research Centre - Queensland (APCRC-Q), Brisbane, QLD, Australia
- Penny L. Jeffery
- School of Biomedical Sciences at the Translational Research Institute (TRI), Queensland University of Technology (QUT), Brisbane, QLD, Australia
- Penny L. Jeffery
- Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD, Australia
- Penny L. Jeffery
- Queensland Bladder Cancer Initiative (QBCI), Brisbane, QLD, Australia
- Penny L. Jeffery
- Australian Prostate Cancer Research Centre - Queensland (APCRC-Q), Brisbane, QLD, Australia
- Patrick B. Thomas
- School of Biomedical Sciences at the Translational Research Institute (TRI), Queensland University of Technology (QUT), Brisbane, QLD, Australia
- Patrick B. Thomas
- Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD, Australia
- Patrick B. Thomas
- Queensland Bladder Cancer Initiative (QBCI), Brisbane, QLD, Australia
- Patrick B. Thomas
- Australian Prostate Cancer Research Centre - Queensland (APCRC-Q), Brisbane, QLD, Australia
- Mahasha P. J. Perera
- School of Biomedical Sciences at the Translational Research Institute (TRI), Queensland University of Technology (QUT), Brisbane, QLD, Australia
- Mahasha P. J. Perera
- Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD, Australia
- Mahasha P. J. Perera
- Queensland Bladder Cancer Initiative (QBCI), Brisbane, QLD, Australia
- Mahasha P. J. Perera
- Australian Prostate Cancer Research Centre - Queensland (APCRC-Q), Brisbane, QLD, Australia
- Mahasha P. J. Perera
- Department of Urology, Princess Alexandra Hospital (PAH), Brisbane, QLD, Australia
- Gary Ng
- Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD, Australia
- Gary Ng
- Department of Medical Oncology, Princess Alexandra Hospital (PAH), Brisbane, QLD, Australia
- Alivia R. Calabrese
- School of Biomedical Sciences at the Translational Research Institute (TRI), Queensland University of Technology (QUT), Brisbane, QLD, Australia
- Alivia R. Calabrese
- Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD, Australia
- Alivia R. Calabrese
- Queensland Bladder Cancer Initiative (QBCI), Brisbane, QLD, Australia
- Alivia R. Calabrese
- Australian Prostate Cancer Research Centre - Queensland (APCRC-Q), Brisbane, QLD, Australia
- Clarissa Nicholls
- School of Biomedical Sciences at the Translational Research Institute (TRI), Queensland University of Technology (QUT), Brisbane, QLD, Australia
- Clarissa Nicholls
- Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD, Australia
- Clarissa Nicholls
- Queensland Bladder Cancer Initiative (QBCI), Brisbane, QLD, Australia
- Nathan J. Mackenzie
- School of Biomedical Sciences at the Translational Research Institute (TRI), Queensland University of Technology (QUT), Brisbane, QLD, Australia
- Nathan J. Mackenzie
- Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD, Australia
- Nathan J. Mackenzie
- Queensland Bladder Cancer Initiative (QBCI), Brisbane, QLD, Australia
- Nathan J. Mackenzie
- Australian Prostate Cancer Research Centre - Queensland (APCRC-Q), Brisbane, QLD, Australia
- Jack Wood
- School of Biomedical Sciences at the Translational Research Institute (TRI), Queensland University of Technology (QUT), Brisbane, QLD, Australia
- Jack Wood
- Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD, Australia
- Jack Wood
- Queensland Bladder Cancer Initiative (QBCI), Brisbane, QLD, Australia
- Laura J. Bray
- Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD, Australia
- Laura J. Bray
- School of Mechanical, Medical and Process Engineering, Queensland University of Technology (QUT), Brisbane, QLD, Australia
- Laura J. Bray
- Australian Research Council (ARC) Training Centre for Cell and Tissue Engineering, Queensland University of Technology (QUT), Brisbane, QLD, Australia
- Ian Vela
- School of Biomedical Sciences at the Translational Research Institute (TRI), Queensland University of Technology (QUT), Brisbane, QLD, Australia
- Ian Vela
- Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD, Australia
- Ian Vela
- Queensland Bladder Cancer Initiative (QBCI), Brisbane, QLD, Australia
- Ian Vela
- Australian Prostate Cancer Research Centre - Queensland (APCRC-Q), Brisbane, QLD, Australia
- Ian Vela
- Department of Urology, Princess Alexandra Hospital (PAH), Brisbane, QLD, Australia
- Erik W. Thompson
- School of Biomedical Sciences at the Translational Research Institute (TRI), Queensland University of Technology (QUT), Brisbane, QLD, Australia
- Erik W. Thompson
- Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD, Australia
- Elizabeth D. Williams
- School of Biomedical Sciences at the Translational Research Institute (TRI), Queensland University of Technology (QUT), Brisbane, QLD, Australia
- Elizabeth D. Williams
- Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD, Australia
- Elizabeth D. Williams
- Queensland Bladder Cancer Initiative (QBCI), Brisbane, QLD, Australia
- Elizabeth D. Williams
- Australian Prostate Cancer Research Centre - Queensland (APCRC-Q), Brisbane, QLD, Australia
- DOI
- https://doi.org/10.3389/fonc.2021.767697
- Journal volume & issue
-
Vol. 11
Abstract
Precision medicine approaches that inform clinical management of individuals with cancer are progressively advancing. Patient-derived explants (PDEs) provide a patient-proximal ex vivo platform that can be used to assess sensitivity to standard of care (SOC) therapies and novel agents. PDEs have several advantages as a patient-proximal model compared to current preclinical models, as they maintain the phenotype and microenvironment of the individual tumor. However, the longevity of PDEs is not compatible with the timeframe required to incorporate candidate therapeutic options identified by whole exome sequencing (WES) of the patient’s tumor. This review investigates how PDE longevity varies across tumor streams and how this is influenced by tissue preparation. Improving longevity of PDEs will enable individualized therapeutics testing, and thus contribute to improving outcomes for people with cancer.
Keywords
